{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:08:33Z","timestamp":1781525313554,"version":"3.54.1"},"reference-count":255,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013291","name":"Huazhong University of Science and Technology Tongji Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["JCZRQN202500308"],"award-info":[{"award-number":["JCZRQN202500308"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2025M772119"],"award-info":[{"award-number":["2025M772119"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017941","name":"Postdoctoral Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2004HBBHJD042"],"award-info":[{"award-number":["2004HBBHJD042"]}],"id":[{"id":"10.13039\/100017941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["2KYC13057\\u201308"],"award-info":[{"award-number":["2KYC13057\\u201308"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203453"],"award-info":[{"award-number":["82203453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372929"],"award-info":[{"award-number":["82372929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503148"],"award-info":[{"award-number":["82503148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118515","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:57:28Z","timestamp":1756904248000},"page":"118515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers"],"prefix":"10.1016","volume":"191","author":[{"given":"Lihua","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaochun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118515_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118515_bib2","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.gendis.2022.04.009","article-title":"Critical involvement of circular RNAs in virus-associated cancers","volume":"10","author":"Zebardast","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2025.118515_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2493","article-title":"Role of the VEGF in virus-associated cancers","volume":"34","author":"Tavakolian","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08657-0","article-title":"HIV immune evasin nef enhances allogeneic CAR t cell potency","author":"Perica","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118515_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-024-00930-x","article-title":"Applications of cell therapy in the treatment of virus-associated cancers","volume":"21","author":"Toner","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118515_bib7","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bangham","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118515_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis b virus DNA integration: implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamadermatol.2024.4607","article-title":"Merkel cell carcinoma and immunosuppression, UV radiation, and merkel cell polyomavirus","volume":"161","author":"Tribble","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.biopha.2025.118515_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","article-title":"Inflammation: the incubator of the tumor microenvironment","volume":"8","author":"Denk","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis c viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41388-025-03295-2","article-title":"Virus-mediated immunosuppression in head and neck cancer","volume":"44","author":"Miyauchi","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118515_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007479","article-title":"TP53\/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma","volume":"11","author":"Yu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8+ t cell:treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118515_bib17","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118515_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12967-024-05069-y","article-title":"HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses t cell activity in hepatocellular carcinoma","volume":"22","author":"Jia","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/cr.2016.153","article-title":"Immunotherapy against cancer-related viruses","volume":"27","author":"Tashiro","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2025.118515_bib21","volume":"2","author":"Carcinogenic HPV infection","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118515_bib22","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2025.118515_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41588-023-01357-3","article-title":"Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma","volume":"55","author":"Puram","year":"2023","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2025.118515_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ng.3178","article-title":"Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism","volume":"47","author":"Hu","year":"2015","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2025.118515_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.molmed.2024.05.009","article-title":"HPV integration and cervical cancer: a failed evolutionary viral trait","volume":"30","author":"Molina","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01875-21","article-title":"High-Risk mucosal human papillomavirus 16 (HPV16) E6 protein and cutaneous HPV5 and HPV8 E6 proteins employ distinct strategies to interfere with interferon regulatory factor 3-Mediated beta interferon expression","volume":"96","author":"Poirson","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2017.07.014","article-title":"Human papillomaviruses and carcinogenesis: well-established and novel models","volume":"26","author":"Viarisio","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib29","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.170093297","article-title":"The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle","volume":"97","author":"Duensing","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118515_bib30","first-page":"71","article-title":"hrHPV E5 oncoprotein: immune evasion and related immunotherapies","volume":"36","author":"de Freitas","year":"2017","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.biopha.2025.118515_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103923","article-title":"Impact of HPV E5 on viral life cycle via EGFR signaling","volume":"139","author":"Ilahi","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.biopha.2025.118515_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2020.10.034","article-title":"HPV post-infection microenvironment and cervical cancerHPV","volume":"497","author":"Yuan","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118515_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"Advances in cervical cancer: current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib35","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib36","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-22-1280","article-title":"Efficacy and safety of the Anti-PD-L1 mab socazolimab for recurrent or metastatic cervical cancer: a phase I Dose-Escalation and expansion study","volume":"28","author":"An","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib37","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-Positive cervical cancer: results from the phase ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib38","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(23)00052-9","article-title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib40","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Ks","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib42","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib45","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib46","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5501","article-title":"In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study","volume":"41","author":"Ray-Coquard","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib49","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ t cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118515_bib50","article-title":"IBI310 plus sintilimab vs. Placebo plus sintilimab in recurrent\/metastatic cervical cancer: a double-blind, randomized controlled trial","author":"Li","year":"2025","journal-title":"Med N. Y. N."},{"key":"10.1016\/j.biopha.2025.118515_bib51","doi-asserted-by":"crossref","first-page":"2203040","DOI":"10.1002\/advs.202203040","article-title":"Single-Nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma","volume":"9","author":"Ou","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.118515_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3776","article-title":"Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human Papillomavirus-Related cervical carcinoma","volume":"4","author":"Lheureux","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118515_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1473-3099(18)30802-8","article-title":"Gender-neutral HPV vaccination in the UK, rising Male oropharyngeal cancer rates, and lack of HPV awareness","volume":"19","author":"Lechner","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118515_bib55","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib56","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent Squamous-Cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","article-title":"Immune landscape of Viral- and Carcinogen-Driven head and neck cancer","volume":"52","author":"Cillo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2025.118515_bib59","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.19.03156","article-title":"Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in combination with pembrolizumab in Anti-PD-1 Treatment-Na\u00efve head and neck squamous cell carcinoma: results from a multicenter, phase II trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib61","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A Toll-Like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118515_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2025.118515_bib63","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib64","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118515_bib66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib67","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1078-0432.CCR-24-1957","article-title":"A phase II basket trial of dual Anti\u2013CTLA-4 and Anti\u2013PD-1 blockade in rare tumors SWOG S1609: vulvar cancers","volume":"31","author":"Chae","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and Cost-Effectiveness of human papillomavirus vaccination through age 45 years in the United States","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib69","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2024.6998","article-title":"Novel combination immunotherapy and clinical activity in patients with HPV-Associated cancers: a nonrandomized clinical trial","volume":"11","author":"Floudas","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and Tumor-Specific vaccine for patients with incurable human papillomavirus 16-Related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib71","article-title":"Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009","volume":"6","author":"St","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2025.118515_bib72","article-title":"PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer","volume":"74","author":"Cs","year":"2025","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.biopha.2025.118515_bib73","article-title":"TCR-engineered t cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nb","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib74","article-title":"A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a t cell receptor reactive to human papillomavirus type 16","volume":"566","author":"M","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118515_bib75","article-title":"Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease","volume":"37","author":"Dm","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2025.118515_bib76","first-page":"37","article-title":"Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors","volume":"40","author":"Paolini","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.biopha.2025.118515_bib77","unstructured":"World Health Organization. Hepatitis B. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b\u3009 (2024)."},{"key":"10.1016\/j.biopha.2025.118515_bib78","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in barcelona clinic liver cancer stage c (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib80","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118515_bib81","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis b virus cccDNA--The holy grail to hepatitis b cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib82","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gutjnl-2023-330414","article-title":"HBV integrations reshaping genomic structures promote hepatocellular carcinoma","volume":"73","author":"Qian","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118515_bib83","article-title":"Hepatitis b virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118515_bib84","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-023-01573-7","article-title":"RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib85","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2009.10.033","article-title":"Mechanisms of HBV-related hepatocarcinogenesis","volume":"52","author":"Neuveut","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib86","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1007\/s00705-017-3462-6","article-title":"Modulation of wnt signaling pathway by hepatitis b virus","volume":"162","author":"Daud","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib87","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/v16091361","article-title":"Hepatitis b viral protein HBx: roles in viral replication and hepatocarcinogenesis","volume":"16","author":"Li","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118515_bib88","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.30553","article-title":"HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K\/AKT signal pathway","volume":"140","author":"Zhu","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.4434","article-title":"The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets","volume":"235","author":"Ringelhan","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2025.118515_bib91","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.19370","article-title":"Plasma Interleukin-10: a likely predictive marker for hepatitis b Virus-Related Acute-on-Chronic liver failure","volume":"14","author":"Wang","year":"2014","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.biopha.2025.118515_bib92","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-018-0048-z","article-title":"Role of nonresolving inflammation in hepatocellular carcinoma development and progression","volume":"2","author":"Yu","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib93","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","article-title":"Phenotypic CD8 t cell profiling in chronic hepatitis b to predict HBV-specific CD8 t cell susceptibility to functional restoration in vitro","volume":"72","author":"Rossi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118515_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib95","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib96","first-page":"2147","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Yang","year":"2015","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.biopha.2025.118515_bib97","doi-asserted-by":"crossref","first-page":"1333923","DOI":"10.3389\/fimmu.2024.1333923","article-title":"DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118515_bib98","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","article-title":"The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications","volume":"131","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib99","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12876-024-03134-w","article-title":"Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Song","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118515_bib100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib101","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib102","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (NCT02915432): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib103","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.07.017","article-title":"Outcomes in the asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"82","author":"Lau","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib105","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-025-56537-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib106","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cpt.2992","article-title":"Modeling of proliferating CD4 and CD8 T-Cell changes to tremelimumab exposure in patients with unresectable hepatocellular carcinoma","volume":"114","author":"Song","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib107","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2025.118515_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib109","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-Dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2025.118515_bib110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3350\/cmh.2017.0111","article-title":"Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib111","first-page":"920","article-title":"Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: a phase II study","volume":"44","author":"Cai","year":"2024","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.biopha.2025.118515_bib112","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"T","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib113","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib114","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-Specific T-Cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118515_bib115","article-title":"Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study","volume":"53","author":"O","year":"2023","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-020-00662-x","article-title":"HBV x protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice","volume":"27","author":"Horng","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2025.118515_bib117","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/biom12030470","article-title":"PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis b","volume":"12","author":"Bunse","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118515_bib118","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed t cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biopha.2025.118515_bib119","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3350\/cmh.2024.0469","volume":"30","author":"Bertoletti","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2352-4642(25)00028-8","article-title":"Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis c virus infection: an international registry study","volume":"9","author":"Gonzalez-Peralta","year":"2025","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.biopha.2025.118515_bib121","unstructured":"World Health Organization. Hepatitis C. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c\u3009 (2024)."},{"key":"10.1016\/j.biopha.2025.118515_bib122","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3350\/cmh.2025.0155","article-title":"Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: a nonnegligible risk to liver-related health","volume":"31","author":"Liu","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib123","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/14656566.2024.2396024","article-title":"Cutting-edge pharmacotherapy for hepatitis c virus infection: a comprehensive review","volume":"25","author":"Liu","year":"2024","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.biopha.2025.118515_bib124","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathol-012414-040323","article-title":"Hepatitis c Virus\u2013Associated cancer","volume":"10","author":"Lin","year":"2015","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.biopha.2025.118515_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2197","article-title":"Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis c and hepatitis e viruses","volume":"31","author":"Laugel","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib126","doi-asserted-by":"crossref","first-page":"17717","DOI":"10.1073\/pnas.0508531102","article-title":"Hepatitis c virus protease NS3\/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118515_bib127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.20011145","article-title":"Binding of the hepatitis c virus envelope protein E2 to CD81 inhibits natural killer cell functions","volume":"195","author":"Tseng","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2007.00261.x","article-title":"Role of hepatitis c virus proteins (C, NS3, NS5A) in hepatic oncogenesis","volume":"38","author":"Kasprzak","year":"2008","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib129","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1038\/sj.onc.1208066","article-title":"Hepatitis c viral proteins interact with Smad3 and differentially regulate TGF-beta\/Smad3-mediated transcriptional activation","volume":"23","author":"Cheng","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118515_bib130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3748\/wjg.v25.i1.42","article-title":"Hepatitis c virus core protein modulates several signaling pathways involved in hepatocellular carcinoma","volume":"25","author":"Mahmoudvand","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118515_bib131","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41467-022-35281-7","article-title":"Identification of human progenitors of exhausted CD8+ t cells associated with elevated IFN-\u03b3 response in early phase of viral infection","volume":"13","author":"Cai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib132","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-Based management of hepatocellular carcinoma: systematic review and Meta-analysis of randomized controlled trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118515_bib133","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis b virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118515_bib134","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib135","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, progress, and challenges to hepatitis c vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118515_bib136","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2025.2452955","article-title":"Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response","author":"Costa","year":"2025","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.biopha.2025.118515_bib138","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered t cells redirected against hepatitis c virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118515_bib139","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13027-020-00317-4","article-title":"The interplay between EBV and KSHV viral products and NF-\u03baB pathway in oncogenesis","volume":"15","author":"Charostad","year":"2020","journal-title":"Infect. Agent. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib140","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-21-3408","article-title":"Facts and hopes in the relationship of EBV with cancer immunity and immunotherapy","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib141","doi-asserted-by":"crossref","first-page":"1297994","DOI":"10.3389\/fimmu.2024.1297994","article-title":"Epstein-Barr virus: the mastermind of immune chaos","volume":"15","author":"Silva","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118515_bib142","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.2023021790","article-title":"A modern view of LGL leukemia","volume":"144","author":"Marchand","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118515_bib143","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3390\/cancers15072133","article-title":"EBV and lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118515_bib144","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Khan","year":"2014","journal-title":"Infect. Agent. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2025.118515_bib146","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-16","article-title":"The long and complicated relationship between Epstein-Barr virus and epithelial cells","volume":"91","author":"Hutt-Fletcher","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib147","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01390-20","article-title":"Epstein-Barr virus episome physically interacts with active regions of the host genome in lymphoblastoid cells","volume":"94","author":"Wang","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk0858","article-title":"Antiviral memory b cells exhibit enhanced innate immune response facilitated by epigenetic memory","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118515_bib149","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1073\/pnas.0605985103","article-title":"Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV\u2019s transforming genes","volume":"103","author":"Altmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118515_bib150","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-023-05923-x","article-title":"Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats","volume":"616","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118515_bib151","doi-asserted-by":"crossref","first-page":"1202117","DOI":"10.3389\/fonc.2023.1202117","article-title":"Pathogenesis and therapeutic implications of EBV-associated epithelial cancers","volume":"13","author":"Low","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib152","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3390\/v13122344","article-title":"Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation","volume":"13","author":"Murata","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118515_bib153","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-020-03075-w","article-title":"Mechanism of EBV inducing anti-tumour immunity and its therapeutic use","volume":"590","author":"Choi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118515_bib154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1476-4598-9-155","article-title":"Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGFbeta-mediated growth inhibition","volume":"9","author":"Lo","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib155","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1038\/srep17663","article-title":"Multiple regulation pathways and pivotal biological functions of STAT3 in cancer","volume":"5","author":"Yuan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118515_bib156","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr virus LMP2A drives b cell development and survival in the absence of normal b cell receptor signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2025.118515_bib157","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/labinvest.2015.69","article-title":"Epstein-Barr virus BZLF1 protein impairs accumulation of host DNA damage proteins at damage sites in response to DNA damage","volume":"95","author":"Yang","year":"2015","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.biopha.2025.118515_bib158","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.7150\/ijbs.16564","article-title":"Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis","volume":"12","author":"Li","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118515_bib159","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","article-title":"Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma","volume":"32","author":"Zhang","year":"2015","journal-title":"Med. Oncol. North. Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib161","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib162","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib163","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib164","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.6010","article-title":"NEOSPACE trial: neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC)","volume":"41","author":"Hui","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib165","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.bjc.6603580","article-title":"Increase in circulating Foxp3+CD4+CD25(high) regulatory t cells in nasopharyngeal carcinoma patients","volume":"96","author":"Lau","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101298","article-title":"CTLA-4 (CD152): a versatile receptor for immune-based therapy","volume":"42","author":"Lingel","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2025.118515_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): a phase II multicenter study","volume":"151","author":"Chen","year":"2024","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib169","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib170","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib171","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.23.01296","article-title":"Impact of an Epstein-Barr virus Serology-Based screening program on nasopharyngeal carcinoma mortality: a Cluster-Randomized controlled trial","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib172","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","article-title":"Burden of gastric cancer","volume":"18","author":"Thrift","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118515_bib173","first-page":"951","article-title":"Epstein-Barr virus-associated gastric cancer: disease that requires special approach","volume":"23","author":"Ignatova","year":"2020","journal-title":"Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc."},{"key":"10.1016\/j.biopha.2025.118515_bib174","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","article-title":"Outlooks on Epstein-Barr virus associated gastric cancer","volume":"66","author":"Naseem","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2025.118515_bib175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein-Barr virus","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2025.118515_bib176","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Cancer genome Atlas research network. Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118515_bib177","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib178","first-page":"139","article-title":"Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study","volume":"43","author":"Xie","year":"2020","journal-title":"J. Immunother. Hagerstown Md 1997"},{"key":"10.1016\/j.biopha.2025.118515_bib179","unstructured":"Peng, Z. et al. A phase 2 study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer (FPN: 1032P)."},{"key":"10.1016\/j.biopha.2025.118515_bib180","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr virus-associated lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118515_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2024.107025","article-title":"The role of c-Myc in Epstein-Barr virus-associated cancers: mechanistic insights and therapeutic implications","volume":"197","author":"Mahdavi","year":"2024","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.biopha.2025.118515_bib182","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118515_bib183","first-page":"7034","article-title":"Selection of new immunotherapy targets for NK\/T cell lymphoma","volume":"12","author":"Lv","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2025.118515_bib184","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2040620718761777","article-title":"Pembrolizumab and its role in relapsed\/refractory classical Hodgkin\u2019s lymphoma: evidence to date and clinical utility","volume":"9","author":"Shindiapina","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biopha.2025.118515_bib186","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118515_bib187","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10238-021-00754-4","article-title":"Programmed cell death-ligand 1 (PD-L1)+ tumour cells and low-reacting programmed cell death 1 (PD1)+ tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus+ diffuse large B-cell lymphoma","volume":"22","author":"Kimura","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib188","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2025.118515_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108192","article-title":"Advances and challenges of immunotherapies in NK\/T cell lymphomas","volume":"26","author":"He","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2025.118515_bib190","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of efficacy of pembrolizumab between Epstein-Barr Virus-Positive and-Negative relapsed or refractory Non-Hodgkin lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2025.118515_bib191","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: from mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib192","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.23_suppl.139","article-title":"Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: results from an investigator-initiated trial","volume":"42","author":"Peng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib193","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR t cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib194","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib196","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib197","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3389\/fimmu.2019.03084","article-title":"KSHV: immune modulation and immunotherapy","volume":"10","author":"Broussard","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118515_bib198","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41467-024-45852-5","article-title":"Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus","volume":"15","author":"Wan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib199","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118515_bib200","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1097\/00002030-199912240-00012","article-title":"Aids and cancer in Africa: the evolving epidemic in Zimbabwe","volume":"13","author":"Chokunonga","year":"1999","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215394","article-title":"KSHV lytic proteins K-RTA and K8 bind to cellular and viral chromatin to modulate gene expression","volume":"14","author":"Kaul","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118515_bib202","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.284.5414.641","article-title":"Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen","volume":"284","author":"Ballestas","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118515_bib203","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbagen.2018.01.020","article-title":"Interleukin-6 potentiates Fc\u03b5RI-induced PGD2 biosynthesis and induces VEGF from human in situ-matured skin mast cells","volume":"1862","author":"McHale","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biopha.2025.118515_bib204","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/v12091034","article-title":"Regulation of KSHV latency and lytic reactivation","volume":"12","author":"Broussard","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118515_bib205","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1097\/00002030-199818000-00018","article-title":"Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi\u2019s sarcoma","volume":"12","author":"Renwick","year":"1998","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib206","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/ijc.34689","article-title":"A prospective cohort study identifies two types of HIV+ kaposi sarcoma lesions: proliferative and inflammatory","volume":"153","author":"Moorad","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib207","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/v13091797","article-title":"Recent advances in developing treatments of Kaposi\u2019s sarcoma Herpesvirus-Related diseases","volume":"13","author":"Naimo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118515_bib208","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00917-17","article-title":"Kaposi\u2019s Sarcoma-Associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes","volume":"8","author":"Host","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.biopha.2025.118515_bib209","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.annonc.2022.03.012","article-title":"Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical kaposi sarcoma (cKS)","volume":"33","author":"Zer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib210","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","article-title":"PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study","volume":"23","author":"Delyon","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib211","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ t cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib212","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-Associated kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2025.118515_bib213","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/s41467-024-49209-w","article-title":"KSHV infection of b cells primes protective t cell responses in humanized mice","volume":"15","author":"Caduff","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib214","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ijc.26428","article-title":"KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction","volume":"131","author":"Dai","year":"2012","journal-title":"Int. J. Cancer J. Int. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib215","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"Biomed. Pharm. Biomedecine Pharm."},{"key":"10.1016\/j.biopha.2025.118515_bib216","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib217","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118515_bib218","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118515_bib219","article-title":"Merkel cell carcinoma, version 1.2024 featured updates to the NCCN guidelines","volume":"22","author":"Schmults","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"10.1016\/j.biopha.2025.118515_bib220","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.18632\/oncotarget.6494","article-title":"Mutational landscape of MCPyV-positive and MCPyV-negative merkel cell carcinomas with implications for immunotherapy","volume":"7","author":"Goh","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118515_bib221","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-10-3363","article-title":"Merkel cell polyomavirus infection, large t antigen, retinoblastoma protein and outcome in merkel cell carcinoma","volume":"17","author":"Sihto","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib222","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2022","article-title":"DNA methyltransferases in virus-associated cancers","volume":"29","author":"Charostad","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib223","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-018-0103-2","article-title":"The biology and treatment of merkel cell carcinoma: current understanding and research priorities","volume":"15","author":"Harms","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188880","article-title":"An update on merkel cell carcinoma","volume":"1878","author":"Sergi","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012426","article-title":"Merkel cell polyomavirus small tumor antigen contributes to immune evasion by interfering with type I interferon signaling","volume":"20","author":"Ohnezeit","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2025.118515_bib226","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1128\/JVI.01786-13","article-title":"The t antigen locus of merkel cell polyomavirus downregulates human Toll-like receptor 9 expression","volume":"87","author":"Shahzad","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib227","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-0395","article-title":"Biomarker analyses investigating disease biology and associations with outcomes in the JAVELIN merkel 200 trial of avelumab in metastatic merkel cell carcinoma","volume":"30","author":"D\u2019Angelo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118515_bib228","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of merkel cell carcinoma by cancer stage and time from diagnosis","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.biopha.2025.118515_bib229","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118515_bib230","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.20.00201","article-title":"Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial","volume":"38","author":"Topalian","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib231","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of First-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib232","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as First-Line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib233","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118515_bib234","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic merkel cell carcinoma: a nonrandomized, Open-Label, international, multicenter phase I\/II study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib235","article-title":"Tumor regression following engineered Polyomavirus-Specific t cell therapy in immune checkpoint Inhibitor-Refractory merkel cell carcinoma","author":"Asano","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2025.118515_bib236","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jdcr.2019.07.006","article-title":"Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced merkel cell carcinoma","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.biopha.2025.118515_bib237","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.suc.2024.11.010","article-title":"Updates in management of Local-Regionally advanced merkel cell carcinoma","volume":"105","author":"Frey","year":"2025","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.biopha.2025.118515_bib238","doi-asserted-by":"crossref","first-page":"1253568","DOI":"10.3389\/fimmu.2023.1253568","article-title":"LAMP1 targeting of the large t antigen of merkel cell polyomavirus results in potent CD4 t cell responses and tumor inhibition","volume":"14","author":"Buchta Rosean","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118515_bib239","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1535-7163.MCT-23-0652","article-title":"First-in-Human stage III\/IV melanoma clinical trial of immune priming agent IFx-Hu2.0","volume":"23","author":"Markowitz","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118515_bib240","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41564-024-01652-7","article-title":"Making HTLV-1 and those affected visible","volume":"9","author":"Rosadas","year":"2024","journal-title":"Nat. Microbiol"},{"key":"10.1016\/j.biopha.2025.118515_bib241","first-page":"2299","article-title":"HTLV-1 persistence and the oncogenesis of adult T-cell leukemia\/lymphoma","volume":"141","author":"Bangham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118515_bib242","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib243","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28424","article-title":"HTLV-1 persistent infection and ATLL oncogenesis","volume":"95","author":"Zuo","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib244","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.coviro.2013.08.010","article-title":"Human T-cell leukemia virus type 1: replication, proliferation and propagation by tax and HTLV-1 bZIP factor","volume":"3","author":"Matsuoka","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2025.118515_bib245","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2014-02-553602","article-title":"The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia\/lymphoma","volume":"123","author":"Cook","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118515_bib246","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-023-00841-7","article-title":"Primary cells from patients with adult t cell leukemia\/lymphoma depend on HTLV-1 tax expression for NF-\u03baB activation and survival","volume":"13","author":"Hleihel","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118515_bib247","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/bloodadvances.2018029322","article-title":"Cells of adult T-cell leukemia evade HTLV-1 Tax\/NF-\u03baB hyperactivation-induced senescence","volume":"3","author":"Shudofsky","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118515_bib248","article-title":"Correction: HTLV-1 bZIP factor enhances T-cell proliferation by impeding the suppressive signaling of Co-inhibitory receptors","volume":"13","author":"Kinosada","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2025.118515_bib249","doi-asserted-by":"crossref","first-page":"15264","DOI":"10.1038\/ncomms15264","article-title":"Cis-perturbation of cancer drivers by the HTLV-1\/BLV proviruses is an early determinant of leukemogenesis","volume":"8","author":"Rosewick","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118515_bib250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-Cell Leukemia-Lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118515_bib251","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fmicb.2019.02235","article-title":"Progress in allogeneic hematopoietic cell transplantation in adult T-Cell Leukemia-Lymphoma","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.biopha.2025.118515_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104495","article-title":"TIGIT: will it be the next star therapeutic target like PD-1 in hematological malignancies?","volume":"204","author":"Liu","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118515_bib253","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-Cell Leukemia-Lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118515_bib254","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.580371","article-title":"CRISPR genome editing applied to the pathogenic retrovirus HTLV-1","volume":"10","author":"Panfil","year":"2020","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"10.1016\/j.biopha.2025.118515_bib255","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.ymthe.2023.03.014","article-title":"Precise excision of HTLV-1 provirus with a designer-recombinase","volume":"31","author":"Rojo-Romanos","year":"2023","journal-title":"Mol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:57:10Z","timestamp":1772823430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225007097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":255,"alternative-id":["S0753332225007097"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118515","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118515"}}